



Dear FOP Community,

Today marks another meaningful step forward for people living with FOP. I am pleased to share that the U.S. Food and Drug Administration (FDA) has approved ATEBRIOZ™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).

This milestone reflects years of dedication from people living with FOP and their families, who have shared their experiences, participated in research and advocated for progress. Researchers, clinicians, global FOP patient organizations, and our partners at Incyte have also worked to advance the science and understanding of this incredibly complex disease. While Mirum has only been part of the FOP community for a short time, we have been inspired by the strength, resilience and determination that have driven this progress.

At Mirum, we are drawn to rare diseases where the challenges are significant and where we believe we can make a meaningful difference. For us, that means going beyond bringing a medicine forward. It means listening, learning and earning trust as a partner to the people and families we serve. We are honored to bring that commitment to the FOP community and look forward to the work ahead.

In the United States, ATEBRIOZ is expected to be available in October. Mirum Access Plus, our patient support program, will be available to help patients, families and healthcare providers navigate treatment access. You can read more about today's approval in our press release linked [here](#).

There is still much more to do, and we are excited to do it alongside you. In the European Union, a marketing authorization application for zilurgisertib is currently under review by the European Medicines Agency, supported by data from Cohort 1 (patients aged 12 years and older) of the PROGRESS study. Our broader work in FOP also continues through the PROGRESS clinical development program evaluating zilurgisertib in children aged 2 to <12 years with FOP. We look forward to continuing to learn from the FOP community, supporting

Mirum Pharmaceuticals, Inc.
989 E. Hillsdale Blvd., Suite 300
Foster City, CA 94404

mirumpharma.com



families and physicians, and working with the urgency and purpose to help move the field forward.

Thank you for welcoming Mirum into this remarkable community. We are honored to be here and to contribute to what comes next.

With gratitude,

Chris Peetz
Chief Executive Officer
Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.
989 E. Hillsdale Blvd., Suite 300
Foster City, CA 94404

mirumpharma.com